Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 49 results:
Author Title Type [ Year
] Filters: Author is Makras, Polyzois [Clear All Filters]
(2018). Irisin in metabolic diseases..
Endocrine. 59(2), 260-274.
(2018). Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?.
Calcif Tissue Int. 103(1), 107-108.
(2018). Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment..
Hormones (Athens). 17(4), 573-579.
(2018). THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis..
Eur J Endocrinol. 179(1), R31-R45.
(2017). Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases..
J Bone Miner Res. 32(6), 1291-1296.
(2017). Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity..
Metabolism. 71, 198-201.
(2017). Periostin and sclerostin levels in juvenile Paget's disease..
Clin Cases Miner Bone Metab. 14(2), 269-271.
(2016). Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease..
J Bone Miner Metab. 34(4), 447-56.
(2016). Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid..
J Clin Endocrinol Metab. 101(9), L89-90.
(2015). Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment..
Expert Opin Ther Targets. 19(3), 299-306.
(2015). Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers..
Metabolism. 64(10), 1291-7.
(2015). Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis..
Expert Opin Investig Drugs. 24(2), 145-57.
(2013). Coexistence of Graves' disease, papillary thyroid carcinoma and unilateral benign struma ovarii: case report and review of the literature..
Metabolism. 62(10), 1350-6.
(2013). Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial..
J Clin Endocrinol Metab. 98(8), 3206-12.
(2013). Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis..
Clin Endocrinol (Oxf). 79(4), 499-503.
(2012). Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass..
Bone. 50(5), 1130-4.
(2012). Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab..
Ther Clin Risk Manag. 8, 295-306.
(2012). Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature..
Hormones (Athens). 11(4), 419-27.
(2012). The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass..
Clin Endocrinol (Oxf). 77(6), 816-22.
(2012). Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?.
Mol Ther. 20(1), 6-7.
(2012). Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis..
J Clin Endocrinol Metab. 97(4), E618-21.
(2011). Denosumab and bisphosphonates: rivals or potential "partners"? A "hybrid" molecule hypothesis..
Med Hypotheses. 77(1), 109-11.
(2011). No effect of rosuvastatin in the zoledronate-induced acute-phase response..
Calcif Tissue Int. 88(5), 402-8.
(2011). Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis..
Hormones (Athens). 10(3), 174-95.
